<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from ICN
Pharmaceuticals, Inc.'s March 31, 2000 Consolidated Condensed Financial
Statements and is qualified in its entirety by reference to such financial
statements.
</LEGEND>
<MULTIPLIER>                                   1,000

<S>                                        <C>
<PERIOD-TYPE>                                    3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                         215,238
<SECURITIES>                                         0
<RECEIVABLES>                                  246,130
<ALLOWANCES>                                   (24,950)
<INVENTORY>                                    139,358
<CURRENT-ASSETS>                               598,140
<PP&E>                                         409,172
<DEPRECIATION>                                 (82,490)
<TOTAL-ASSETS>                               1,496,855
<CURRENT-LIABILITIES>                          147,748
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           789
<OTHER-SE>                                     699,143
<TOTAL-LIABILITY-AND-EQUITY>                 1,496,855
<SALES>                                        159,340
<TOTAL-REVENUES>                               192,340
<CGS>                                           60,766
<TOTAL-COSTS>                                   60,766
<OTHER-EXPENSES>                                 4,001
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              15,221
<INCOME-PRETAX>                                 38,448
<INCOME-TAX>                                    11,111
<INCOME-CONTINUING>                             27,399
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    27,399
<EPS-BASIC>                                        .35
<EPS-DILUTED>                                      .34


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission